Surface Oncology gets FDA fast track designation for hepatocellular carcinoma

Surface Oncology’s (NASDAQ:SURF) SRF388 received FDA fast track designation for the treatment of hepatocellular carcinoma in patients who have previously been treated with standard therapies.

SRF388 is a fully human anti-interleukin-27 antibody designed to inhibit the activity of interleukin-27, an immunosuppressive cytokine.

In a statement, Rob Ross, M.D., Surface Oncology’s CMO, said “There is a significant need to expedite the development of new therapies to treat liver cancer as the five-year survival for patients with unresectable or metastatic liver cancer is less than 5%.”

Surface Oncology is currently enrolling patients with advanced solid tumors in a Phase 1 study. The company plans to expand the study to include liver and kidney cancer indications to further evaluate SRF388 as a monotherapy and in combination with other cancer therapies.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.